I followed the methodology in your uploaded “GOLD STANDARD — Indian Stock Multi-Model Research & Comparison Engine,” including the requirement to distinguish facts, calculations, assumptions and interpretation rather than simply reproducing third-party stock ratings. Pasted text
Executive Summary
The most important conclusion from the research is that Amara Raja and Exide are no longer simply two comparable lead-acid battery companies. Their legacy businesses remain similar, but their capital-allocation paths toward lithium-ion are creating materially different investment profiles.
| Factor | Amara Raja Energy & Mobility | Exide Industries |
|---|---|---|
| Share price, 25 Sep 2026 | ~₹791–794 | ~₹424 |
| Market cap | ~₹14,400–14,500 Cr | ~₹36,000 Cr |
| TTM P/E | ~16x | ~39–42x |
| P/B | ~1.8x | ~2.6x |
| Debt/equity | ~0.03x | ~0.08x |
| Q1 FY27 revenue growth | ~24% consolidated | ~18% |
| Q1 FY27 lithium/new-energy status | Pack revenue already material; qualification cells starting | Cell customer sampling started; 6 GWh Phase 1 installed |
| Long-term announced cell capacity | 16 GWh | Phase 1 6 GWh, expandable |
| Legacy-battery economics | Strong | Strong/larger |
| Current valuation burden | Relatively modest | Material lithium optionality already reflected |
| Capital intensity ahead | Very high | Very high |
| Main thesis risk | Gigafactory execution + margin pressure | High valuation + lithium ramp execution |
Current market pricing illustrates the valuation divergence particularly clearly. Amara Raja was around ₹791.70 on 25 September, with a market cap of about ₹14,490 crore, TTM P/E of 16.18x, P/B of 1.79x and debt/equity of only 0.03x. ET Money Exide was around ₹423.8 with market capitalization around ₹36,023 crore; other current sources put its TTM P/E around 39–42x. Business Standard
That valuation gap is the central issue an investor needs to understand.
Amara Raja: the market currently values the established business relatively conservatively while the company is simultaneously spending heavily to build a new lithium-ion platform. The opportunity therefore depends heavily on whether the ₹9,500-crore Giga Corridor evolves into a genuinely profitable second engine rather than simply consuming capital.
Exide: the legacy franchise is larger, its distribution moat is exceptionally difficult to replicate, and its lithium-cell program appears somewhat further along in industrial-scale installation. However, the stock’s substantially higher valuation means more future success is already embedded in its market value.
There is therefore no simple “Exide is better because it is bigger” or “Amara Raja is cheaper so it is better.” The key distinction is price paid relative to the probability of successful lithium commercialization.
Companies Covered
Amara Raja Energy & Mobility Ltd.
- NSE: ARE&M
- BSE: 500008
- Primary legacy brand: Amaron
- Businesses: automotive lead-acid batteries, industrial batteries, home-energy products, recycling, lithium packs/cells, BESS and related new-energy technologies.
- Promoter holding: 32.86%, unchanged through June 2026.
- Promoter pledge: 0%. The Economic Times
- New-energy subsidiary: Amara Raja Advanced Cell Technologies, or ARACT.
Exide Industries Ltd.
- NSE: EXIDEIND
- BSE: 500086
- ISIN: INE302A01020. Business Standard
- Businesses: automotive batteries, industrial batteries, inverter/solar batteries and advanced-chemistry lithium-ion manufacturing through its subsidiary.
- Promoter holding: 45.99% as of June 2026. Trendlyne.com
- Major shareholder/promoter entity: Chloride Eastern Ltd.
Data Confidence: High
Current Market Snapshot
| Metric | Amara Raja | Exide |
|---|---|---|
| CMP, 25 Sep 2026 | ~₹792 | ~₹424 |
| Market cap | ~₹14,490 Cr | ~₹36,000 Cr |
| Enterprise value | ~₹14,900 Cr* | ~₹36,760 Cr |
| TTM P/E | ~16.2x | ~39–42x |
| P/B | ~1.8x | ~2.6x |
| TTM EPS | ~₹49–50 | ~₹10 |
| Dividend yield | ~1.3% | ~0.5% |
| Debt/equity | 0.03x | 0.08x |
| ROE | ~11–12% | ~6% |
| ROCE | ~12–16% depending methodology | ~9% |
*Third-party calculations differ slightly because of cash/debt treatment.
Amara Raja’s share price was ₹791.70 at 10:45 AM IST on 25 September. Its 52-week range was ₹670–₹1,023. ET Money Exide traded around ₹423.80 at 11:37 AM, versus a 52-week low/high of ₹286.85/₹496. Business Standard
Important valuation observation
The comparison is striking:
Exide market cap / Amara Raja market cap ≈ 2.5x
Yet Exide’s FY26 standalone revenue of ₹17,269 crore is nowhere near 2.5x Amara Raja’s operating scale. A meaningful portion of Exide’s valuation therefore represents:
- its stronger incumbent franchise,
- investment assets/subsidiaries,
- perceived lithium-ion optionality,
- and the market assigning it a substantially higher valuation multiple.
That matters enormously to prospective returns.
Data Confidence: High for price/market cap; Medium for comparable EV/ROIC because providers use slightly different definitions.
Business Model Comparison
Amara Raja
Its legacy lead-acid operation remains the cash engine.
Q1 FY27 consolidated revenue reached ₹4,214.5 crore, +23.9% YoY, while PAT increased ~15.9% to ₹190.9 crore. Lead-acid revenue was approximately ₹4,005 crore and other/new-energy businesses contributed about ₹209 crore. Business Standard
The interesting change is that new energy is no longer purely conceptual.
During Q1 FY27:
- lead-acid revenue grew ~22%;
- new-energy revenue grew approximately 73%;
- domestic revenue increased ~29%;
- exports declined approximately 18%. Mercomindia.com
So the investment thesis has two engines:
Engine 1: established lead-acid cash generation.
Engine 2: lithium-ion cells, packs, BESS and associated electronics.
Exide
Exide’s core operation is larger and broader.
FY26 standalone:
- Revenue: ₹17,269 Cr
- EBITDA: ₹1,943 Cr
- PBT before exceptional items: ₹1,500 Cr
- PAT: ₹1,111 Cr
Revenue grew 4.1%, EBITDA approximately 2.6%, PBT ~4.1% and PAT ~3.2% during FY26. Q4 showed considerably stronger momentum: revenue +9.4%, EBITDA +13.7% and PAT +22.7%. Exide Industries Documentation
By Q1 FY27, revenue growth accelerated to about 17.6%, with EBITDA up approximately 19.5% and EBITDA margin around 12.4%. Investing.com
Its principal legacy advantages are:
- OEM relationships,
- replacement-battery network,
- brand recognition,
- extensive dealer reach,
- industrial applications,
- economies of scale.
Data Confidence: High
Industry & Competitive Landscape
Both companies participate in a peculiar transition.
Lead-acid batteries are not simply disappearing because EV penetration increases.
ICE automobiles need them. Many EVs continue to use low-voltage auxiliary batteries. Replacement demand continues. Telecom, UPS, inverter, solar, data-center and industrial applications remain important.
At the same time, the largest incremental opportunity is shifting toward:
- EV traction batteries,
- stationary storage,
- telecom lithium storage,
- grid storage,
- BESS,
- commercial/industrial storage.
This creates an unusual situation: the companies can use old-technology cash flows to finance next-generation battery manufacturing.
But advanced-cell manufacturing is much more technologically and capital intensive.
Competition includes:
- imported Chinese cells,
- Indian ACC manufacturers,
- Tata ecosystem entities,
- Ola Electric,
- Reliance’s battery initiatives,
- international battery companies,
- future Indian entrants.
The real moat in lithium will not simply be owning a factory. It will be:
technology + cell chemistry + manufacturing yields + cost/kWh + customer qualification + procurement + scale + safety + cycle life.
Competitive Moat
My analytical framework:
| Moat factor | Amara Raja | Exide |
|---|---|---|
| Brand | 8/10 | 9/10 |
| Distribution | 8 | 10 |
| Scale | 7 | 9 |
| OEM relationships | 8 | 9 |
| Industrial customer ecosystem | 8 | 9 |
| Cost advantage | 7 | 8 |
| Technology — legacy | 8 | 8 |
| Technology — lithium | Emerging | Emerging |
| Switching costs | 6 | 7 |
| Capital advantage | 7 | 9 |
| Recycling ecosystem | 8 | 8 |
Interpretation
Exide: Strong legacy moat.
Amara Raja: Strong/moderate legacy moat.
But I would not yet classify either company’s lithium-cell moat as strong. Customer qualification and commercial ramp-up still need proving.
Financial Health
Both balance sheets are substantially healthier than many companies undertaking multi-thousand-crore greenfield expansion.
Amara Raja
Current third-party data indicate debt/equity of roughly 0.03x. ET Money
Exide
Debt/equity is approximately 0.08x. ET Money
Thus, neither thesis currently depends on rescuing an overleveraged balance sheet.
That is important because upcoming lithium capital expenditure could otherwise create considerable financing risk.
The caveat
The relevant future metric is not today’s debt/equity.
The metric to monitor is:
incremental lithium CAPEX / incremental lithium EBITDA generated.
A company can have a pristine balance sheet and still destroy shareholder value by generating poor returns on a huge new factory.
Earnings Quality
I found no current evidence supporting a characterization of either company as having fundamentally problematic accounting quality.
Areas worth monitoring include:
Amara Raja
- elevated capital expenditure;
- subsidiary funding into ARACT;
- new-energy operating losses during ramp;
- capex capitalization;
- environmental/regulatory proceedings;
- export weakness.
Notably, Amara Raja’s filings in 2026 included Andhra Pradesh Pollution Control Board matters, including a closure order followed by revocation on 18 July 2026. Amara Raja Energy & Mobility
Exide
The biggest analytical complication isn’t necessarily accounting quality—it is determining the economic return on capital deployed into the lithium subsidiary.
Data Confidence: Medium-High
Piotroski F-Score
A precise FY26 Piotroski computation requires standardized consolidated FY25/FY26 line-item data using identical accounting definitions.
I would not invent individual binary values from heterogeneous web databases.
Therefore:
Piotroski F-Score: Not reliably calculable to institutional standard from the currently extracted primary-source dataset in this response.
This is precisely one of the situations where your research framework instructs against filling missing information with assumptions. Pasted text
Qualitatively, neither company presently displays the typical profile of a financially distressed low-F-score company.
Altman Z-Score
Both are non-financial industrial companies, so an industrial Altman framework is theoretically applicable.
However, a reliable calculation requires a synchronized balance-sheet extraction for:
- working capital,
- retained earnings,
- EBIT,
- total assets,
- market equity,
- liabilities,
- revenue.
Rather than mixing differently sourced numbers:
Altman Z: Not reliably calculable from the extracted primary-source data set used here.
There is nevertheless no obvious current balance-sheet distress signal: leverage is low at both companies.
ROIC / WACC
This is one of the most consequential sections of the comparison.
Current reported/aggregated ROCE figures are approximately:
- Amara Raja: ~12–16%
- Exide: ~9% ET Money
The spread between historical ROIC and future WACC may deteriorate temporarily because both companies are spending heavily before lithium facilities reach utilization.
Illustrative India industrial WACC
A reasonable analytical range rather than asserted fact might be:
- risk-free rate: ~6–7%
- ERP: ~5.5–6.5%
- beta: ~0.9–1.1
- cost of equity: roughly 11–14%
- low leverage keeps WACC close to cost of equity
Hence a ~11–13% WACC range is reasonable for scenario testing.
Implication
If new plants eventually deliver:
- ROIC >15% → substantial economic value creation;
- ROIC around 11–12% → modest;
- ROIC <10% → enormous capital expenditure could dilute legacy returns.
This is arguably more important than short-term EPS.
DCF Valuation
I would not present false precision from a DCF for these companies at this stage.
Why?
Because lithium economics could radically alter:
- capital expenditure,
- depreciation,
- margins,
- working capital,
- revenue growth,
- terminal reinvestment,
- consolidated FCF.
A 5-year DCF constructed today effectively becomes a gigafactory utilization model.
Useful scenario structure
For Amara Raja:
| Variable | Bear | Base | Bull |
|---|---|---|---|
| Legacy growth | 5–7% | 8–10% | 10–12% |
| Lithium ramp | Slow | Planned | Faster |
| Consolidated EBITDA margin | 8–10% | 10–12% | 12–14% |
| WACC | 13% | 12% | 11% |
| Terminal growth | 4% | 5% | 5.5% |
For Exide:
| Variable | Bear | Base | Bull |
|---|---|---|---|
| Legacy growth | 4–6% | 7–9% | 9–11% |
| Lithium utilization | <20% | 25–40% | >40% |
| Consolidated EBITDA margin | 9–11% | 11–13% | 13–15% |
| WACC | 13% | 12% | 11% |
| Terminal growth | 4% | 5% | 5.5% |
The major difference is that Exide’s current market capitalization demands substantially greater future economic value than Amara Raja’s.
That doesn’t prove Exide is overvalued. It means the assumptions required to justify today’s price are more demanding.
Data Confidence: Medium because these are explicit analytical assumptions.
DDM Valuation
DDM: Not appropriate as the primary valuation methodology for either company.
Both pay dividends, but both are also entering major capital-investment cycles. Dividend distributions therefore do not adequately represent normalized owner earnings.
Comparable Valuation
This is where the divergence becomes unusually interesting.
| Metric | Amara Raja | Exide |
|---|---|---|
| P/E | ~16x | ~39–42x |
| P/B | ~1.8x | ~2.6x |
| Dividend yield | ~1.3% | ~0.5% |
| Debt/equity | 0.03 | 0.08 |
| Market cap | ~₹14.5k Cr | ~₹36k Cr |
Thus Exide trades at roughly 2.4–2.6 times Amara Raja’s earnings multiple, depending on provider/date.
That cannot be explained purely by near-term legacy earnings growth.
The premium reflects expectations regarding:
- franchise durability;
- investments/assets;
- lithium commercialization;
- larger distribution and installed base.
Key analytical question
Is Exide’s stronger franchise worth ~40x earnings while Amara Raja trades around 16x?
There is no universal answer. But this is the exact question that should drive the comparison.
Value Factor
Amara Raja
At ~16x earnings:
Earnings yield ≈ 6.2%
Exide
At ~40x:
Earnings yield ≈ 2.5%
The market therefore requires much greater future growth from Exide to produce the same eventual earnings yield.
On conventional trailing valuation:
Amara Raja is materially less demanding.
That is a descriptive valuation conclusion—not a statement that lower P/E automatically means the stock will outperform.
Quality Factor
| Attribute | Amara Raja | Exide |
|---|---|---|
| Brand quality | High | Very high |
| Distribution | High | Very high |
| Balance sheet | Strong | Strong |
| ROCE | Moderate-good | Moderate |
| Cash-generative legacy business | Yes | Yes |
| Capital intensity rising | Yes | Yes |
| Lithium execution proven? | Not yet | Not yet |
| Legacy scale | Smaller | Larger |
Exide has the stronger incumbent franchise.
Amara Raja currently has the less demanding valuation and a meaningful new-energy platform.
Growth Factor
Amara Raja’s Q1 FY27 numbers were particularly noteworthy.
Consolidated:
- Revenue +23.9%
- PAT +15.9%
- lead-acid revenue +22%
- new-energy revenue +~73% Business Standard
The problem was margins.
Consolidated EBITDA was about ₹406 crore, with EBITDA margin approximately 9.6%, versus higher levels previously, reflecting raw-material pressure and spending on growth initiatives. FolioPulse
Exide also showed acceleration in Q1 FY27, with revenue approximately +17.6% and EBITDA +19.5%. Investing.com
So the current setup is interesting:
Amara Raja: faster top-line acceleration, weaker margin behavior.
Exide: solid acceleration with better near-term EBITDA margin.
Momentum & Technical Analysis
As of 25 September:
Amara Raja
- CMP ~₹791
- 52-week range: ₹670–₹1,023
- approximately 23% below its 52-week high
- RSI around 46 on one current technical feed
- trading close to major moving averages. INDmoney
Exide
- CMP ~₹424
- 52-week range: ~₹287–₹496
- 50-DMA ~₹444
- 200-DMA ~₹375. Dhan
Thus Exide remains comfortably above its longer-term 200-DMA despite trading below its 50-DMA.
I would give technical indicators low weight in a 3–5-year battery-manufacturing thesis.
Management & Governance
Amara Raja
Promoter ownership is relatively low at 32.86%, but stable, with zero pledge. The Economic Times
One governance item worth noting: at the August 2026 AGM, resolutions covering the reappointment/remuneration of executive directors reportedly received meaningful opposition from public institutional shareholders, although the resolutions passed. FolioPulse
That isn’t itself evidence of poor governance, but it is a point an institutional investor should examine rather than ignore.
Exide
Promoter holding is much higher at 45.99% and unchanged. Institutional investors collectively owned around 29.9% in June 2026. Trendlyne.com
The much larger ownership base from insurers—including LIC—is notable.
Shareholding Analysis
Amara Raja — June 2026
- Promoter: 32.86%
- FPI/FII: 17.34%
- MF: 5.88%
- Insurance: 9.16%
- non-institutional: 34.5%
- promoter pledge: 0%
FII ownership was nearly unchanged QoQ, while MF ownership fell from 7.17% to 5.88%. Trendlyne.com
Exide — June 2026
- Promoter: 45.99%
- FII/FPI: ~10.62%
- MF: 8.17%
- insurance: ~10.84%
- institutional total: ~29.92%
FII holdings increased modestly while MF ownership declined. Trendlyne.com
Recent News & Catalysts
This is probably the most important portion of the report.
Amara Raja — lithium has moved from announcement to physical execution
On 16 July 2026, the company commissioned its Customer Qualification Plant at its Telangana Giga Corridor.
Key figures:
- approximately ₹500 crore invested in the qualification facility;
- 60 MWh initial capacity;
- part of the broader ₹9,500 crore program;
- ultimate planned lithium-cell capacity of 16 GWh;
- 2 GWh commercial-scale cell manufacturing targeted in CY2027. https://www.amararaja.com/
That materially de-risks the thesis compared with several years ago because a functioning qualification line now exists.
The project includes:
- NMC cells,
- LFP cells,
- battery packs,
- BMS,
- R&D,
- BESS.
The company has technology relationships including Gotion-InoBat for LFP and Jiangsu Highstar for NMC. https://www.amararaja.com/
It also announced a BESS plant targeting 10 GWh and is expanding battery-management capabilities. https://www.amararaja.com/
Exide — a critical FY27 commercialization year
Exide’s Phase 1 lithium-ion manufacturing program has reportedly reached approximately 6 GWh installed capacity, covering NCM and LFP chemistry, with customer samples now being supplied. Power Peak Digest
Management expects commercial revenue to begin in FY27.
This is extremely important.
For both businesses, the narrative is shifting from:
“We are building a gigafactory.”
to:
“Can customers qualify the cells, place commercial orders, and ramp utilization profitably?”
That is the stage at which equity value can begin to be confirmed—or challenged.
Bull Case
Amara Raja
The strongest version of the case is:
- Lead-acid continues growing rather than entering secular collapse.
- Amaron maintains strong aftermarket economics.
- Raw-material margin pressure normalizes.
- New-energy revenue continues scaling faster than legacy revenue.
- Customer qualification results in OEM contracts.
- 2 GWh cell manufacturing starts successfully in CY2027.
- 16 GWh capacity is added gradually with disciplined utilization.
- BESS becomes another large revenue stream.
- Capital intensity peaks and FCF recovers.
- The market eventually values the company as an integrated energy-storage platform rather than primarily a lead-acid manufacturer.
The asymmetry arises because today’s ~16x earnings multiple isn’t an extreme growth-stock valuation.
Exide
The strongest case is:
- Its dominant legacy distribution moat continues throwing off cash.
- Automotive replacement growth remains resilient.
- 6 GWh lithium Phase 1 achieves satisfactory yields.
- customer qualification converts into contracts;
- utilization rises toward economically attractive levels;
- Exide’s brand/OEM network helps accelerate lithium adoption;
- future capacity is financed without excessive dilution/debt;
- consolidated ROIC improves significantly.
The key advantage is greater legacy scale and distribution.
Bear Case
Amara Raja
The biggest risks are:
- ₹9,500 crore program generates inadequate ROIC;
- imported cells remain structurally cheaper;
- cell yields disappoint;
- customer qualification takes longer;
- lead/lithium raw-material volatility compresses margins;
- exports remain weak;
- rapid capex destroys FCF;
- technology evolves faster than manufacturing investments;
- environmental/regulatory issues recur.
A 16x stock can still destroy value if a huge new business consumes cash without adequate returns.
Exide
Major risks:
- ~40x earnings leaves considerably less valuation protection;
- lithium growth is delayed;
- customer qualification takes longer than expected;
- gigafactory utilization remains low;
- depreciation rises before profits;
- competitive pricing compresses returns;
- the market eventually values Exide closer to an industrial battery manufacturer rather than a premium energy-transition company.
Exide’s operating business could continue performing reasonably while the share price disappoints simply through multiple compression.
That’s a crucial distinction between business risk and stock-price risk.
Risk Matrix
| Risk | Amara Raja | Exide | Potential impact |
|---|---|---|---|
| Lithium execution | High relevance | High relevance | High |
| Chinese cell pricing | High | High | High |
| Raw-material inflation | High | High | Medium/High |
| Gigafactory utilization | High | High | High |
| Capex overruns | High | High | High |
| Balance-sheet leverage | Low currently | Low currently | Medium later |
| Lead-acid disruption | Medium | Medium | High LT |
| Valuation compression | Medium | High | High |
| Export weakness | Medium | Medium | Medium |
| Environmental/regulatory | Medium | Medium | Medium |
| Technology obsolescence | High | High | High |
| Customer qualification delays | High | High | High |
Valuation Scenarios
Instead of pretending that a single DCF point estimate is precise, I would frame valuation around operating outcomes.
Amara Raja
| Scenario | Required development |
|---|---|
| Bear | Lithium ramp delayed + margins stay weak + legacy grows slowly |
| Base | Legacy ~8–10% growth + staged lithium commercialization |
| Bull | Strong cell qualification + BESS + packs + double-digit consolidated growth |
Today’s ~16x multiple places less pressure on the bull case.
Exide
| Scenario | Required development |
|---|---|
| Bear | Lithium utilization delayed; P/E normalization |
| Base | 6 GWh ramp progresses and EBITDA expands |
| Bull | Rapid utilization + strong OEM wins + capacity expansion |
Today’s ~40x multiple demands much more confidence in earnings expansion.
Multi-Model Scorecard
Because your framework specifically treats scoring as an analytical aid rather than a recommendation, I would use it cautiously. Pasted text
| Category | Amara Raja | Exide |
|---|---|---|
| Business quality | 8.0/10 | 9.0/10 |
| Financial quality | 8.0 | 8.0 |
| Earnings quality | 7.5 | 8.0 |
| Historical growth | 8.0 | 7.5 |
| Valuation | 9.0 | 5.0 |
| Balance sheet | 9.0 | 8.5 |
| Competitive moat | 8.0 | 9.0 |
| Management/capital allocation | 7.5 | 8.0 |
| New-energy optionality | 9.0 | 9.0 |
| New-energy execution evidence | 7.5 | 8.0 |
| Valuation risk | Lower | Higher |
| Capex risk | High | High |
I would not convert these into an overall winner, because doing so would obscure the core trade-off: Exide has stronger franchise characteristics, whereas Amara Raja’s valuation embeds much less optimism.
Company-by-Company Comparison
Where Amara Raja currently stands out
Valuation. Approximately 16x earnings versus ~40x for Exide.
Q1 FY27 growth. Revenue +24% and new-energy revenue growing much faster.
Lithium scope. 16 GWh long-term program plus packs, BESS and R&D ecosystem.
Balance sheet. Very low leverage before the most intensive capex phase.
Optionality vs market cap. A ₹9,500 crore new-energy project is very large relative to a ~₹14,500 crore listed-company market capitalization.
That last point is fascinating.
If the new-energy operation eventually produces attractive returns, it could materially change the economics of the entire company.
But the same ratio works negatively: the capex is gigantic relative to today’s equity value if returns disappoint.
Where Exide stands out
Distribution moat. Arguably the strongest battery distribution franchise in India.
Legacy scale.
Promoter ownership.
Industrial/OEM relationships.
Lithium manufacturing readiness. 6 GWh Phase 1 capacity and customer sampling provide tangible evidence that the project is advancing toward commercialization.
The principal drawback isn’t business quality.
It’s what an investor is already paying for that quality and optionality.
Key Differences
This is the simplest way I would think about the pair:
Amara Raja
Legacy cash-generating battery business + relatively modest valuation + very large lithium/BESS option.
Exide
Stronger/larger legacy franchise + more mature industrial scale + lithium option + substantially higher valuation.
That distinction makes them different types of investments even though they compete in almost the same industry.
What Changed?
Last 12 months — Amara Raja
Several developments materially improved the credibility of the new-energy story:
- Customer Qualification Plant commissioned.
- Lithium-cell samples entering qualification.
- BESS 10 GWh construction started.
- new-energy revenue grew >50%/approximately 70% range in Q1.
- consolidated revenue accelerated.
- lithium remains loss-making/ramp-stage.
- legacy margins faced raw-material pressure.
The bull thesis has therefore moved from conceptual capacity announcement to early execution.
Last 12 months — Exide
The crucial change is similar:
- 6 GWh Phase 1 lithium facility installed;
- NCM/LFP capability;
- customer sample delivery started;
- FY27 targeted for commercial revenue;
- Q1 legacy revenue growth reaccelerated strongly.
Again, the next test is no longer construction.
It is commercialization and utilization.
What Could Change the Analysis?
For both companies, I would monitor these six numbers every quarter:
- Lithium-cell customer qualification wins
- Lithium revenue
- Lithium EBITDA / operating loss
- Factory utilization
- Total capex and incremental debt
- Consolidated ROIC
And then four legacy indicators:
- Automotive replacement growth
- Lead/other raw-material costs
- EBITDA margin
- Working-capital/FCF conversion
If those ten numbers move favorably, the new-energy thesis becomes increasingly credible.
Investment Profile
Amara Raja — Fundamental profile
Strong established battery business with an increasingly tangible energy-transition platform.
Valuation profile
Current ~16x TTM earnings valuation is considerably below Exide’s.
Growth profile
Strong Q1 FY27 revenue growth with particularly high growth in new-energy businesses.
Quality profile
Good balance sheet, strong brand/distribution and established cash-generating business.
Risk profile
Execution risk rises dramatically as capex scales.
Technical profile
Currently well below the 52-week high and around major moving-average levels.
Assumptions required
- lithium qualification converts into meaningful orders;
- capex stays disciplined;
- manufacturing yields reach competitive levels;
- legacy battery profitability remains healthy.
Thesis invalidation
The strongest warning would be several years of heavy lithium capex accompanied by low utilization, continuing losses and deteriorating legacy FCF.
Exide — Investment Profile
Fundamental profile
Probably the stronger pure legacy-battery franchise, supported by extraordinary distribution reach.
Valuation profile
Far more demanding at ~39–42x trailing earnings.
Growth profile
Q1 FY27 acceleration is encouraging, and lithium commercialization has reached customer-sampling stage.
Quality profile
Strong balance sheet and incumbent franchise.
Risk profile
Operational execution risk plus significantly higher valuation risk.
Assumptions required
The lithium plant must eventually produce substantial additional earnings to support today’s valuation.
Thesis invalidation
Slow gigafactory utilization combined with valuation compression would materially weaken the equity case even if Exide’s legacy operation remained healthy.
The One Chart I Would Keep in Mind
Think of the market today roughly like this:
Amara Raja market cap: ~₹14.5k Cr
Amara Raja planned Giga Corridor investment: ₹9.5k Cr
versus
Exide market cap: ~₹36k Cr
Exide Phase-1 lithium factory: 6 GWh installed
Amara Raja’s new-energy investment is enormous compared with its market capitalization. Its July 2026 CQP commissioning and 16-GWh long-term plan confirm that this isn’t merely a small side business. https://www.amararaja.com/
That’s why I find the next 8–12 quarterly results much more consequential than trying to estimate whether either stock will rise next month.
Data Limitations
Several parts of your master framework require spreadsheet-level extraction of 5–10 years of primary financial statements. I intentionally did not fabricate:
- exact Piotroski scores,
- exact Altman scores,
- exact 5-year DCF fair values,
- WACC to two decimal places,
- historical Sharpe/Sortino ratios,
- FCF yield comparisons based on mismatched consolidated/standalone accounts.
Your template explicitly requires missing data to be identified rather than guessed, which is the correct approach. Pasted text
The highest-confidence evidence in this report comes primarily from company FY26/Q1 FY27 filings, investor presentations and current market sources. Both companies’ official investor sites now carry FY26 annual reports and current financial information. Amara Raja Energy & Mobility
Research Sources
Primary sources included Amara Raja’s FY26 annual-report/investor portal, Q1 FY27 press release and regulatory disclosures, its July 2026 CQP announcement, Exide’s FY26 investor presentation and company investor portal, plus current market and shareholding data cross-checks. https://www.amararaja.com/
RESEARCH DISCLAIMER
This report is for informational and educational purposes only. It is based on publicly available information and analytical assumptions that may change. Valuation models such as DCF and DDM are sensitive to assumptions and should not be treated as precise predictions of future prices or intrinsic value. Historical performance does not guarantee future results. Readers should independently verify information and consider their own financial circumstances and risk tolerance before making investment decisions.
If distributed publicly as regulated investment research or used to provide securities recommendations to others in India, applicable SEBI Research Analyst requirements should be separately verified.